

Neuromyelitis optica (NMO) and myelin oligodendrocyte glycoprotein antibody disease (MOGAD) are autoimmune conditions that affect the central nervous system (CNS). These diseases occur when the body’s immune system attacks its own nervous system, especially the optic nerves, spinal cord, and brain. This can lead to vision loss, muscle weakness, numbness, pain, and bladder or bowel problems.
The NMO with MOG Antibody Profile checks for the presence of two specific antibodies in the blood: aquaporin-4 (AQP4) IgG antibodies, which are strongly linked to NMOSD (a severe form of NMO or Neuromyelitis Optica Spectrum Disorder), and myelin oligodendrocyte glycoprotein (MOG) IgG antibodies, which indicate MOGAD. The detection of these antibodies helps the doctor confirm the diagnosis, especially when the symptoms of these conditions overlap with other central nervous system disorders like multiple sclerosis (MS). Accurate diagnosis is important because the treatment and disease progression differ across these conditions.
Individuals with one or more of the following symptoms may benefit from taking the NMO with MOG Antibody Profile: weakness or numbness in the arms or legs, tight or painful muscle spasms in the arms or legs, and discomfort or unusual sensations in the limbs. Some may also experience issues related to bladder control, bowel movements, or sexual dysfunction. These symptoms may indicate inflammation or damage in the brain, spinal cord, or optic nerves.
This test helps in early diagnosis of NMOSD and MOGAD, especially when imaging results are inconclusive, which, with timely treatment, can help prevent irreversible damage to the Central nervous system (CNS).
No special preparation is required for the NMO with MOG Antibody Profile. Inform the doctor about all the medications (e.g., immunosuppressants, steroids, etc.) and supplements currently being taken, as some of them may affect the test results, so your doctor may adjust the dose or ask you to pause them before the test.
Test result ranges are approximate and may differ slightly between labs, depending on the methodology and laboratory guidelines. Do not self-medicate, and always consult a doctor to understand the test results correctly.
Please note: This is an outsourced test. The sample is collected by TATA 1MG and processed at a NABL accredited partnered lab.
The NMO with MOG Antibody Profile is a group of blood tests that checks for two specific antibodies linked to nerve-related conditions:
1. Aquaporin-4 (AQP4) IgG antibodies – These antibodies attack water channels in the brain and spinal cord, especially the optic nerve. Their presence helps diagnose a condition called neuromyelitis optica spectrum disorder (NMOSD).
2. Myelin oligodendrocyte glycoprotein (MOG) IgG antibodies – These antibodies damage the protective covering (myelin) around nerves. They are linked to MOG antibody disease (MOGAD), which is different from both NMOSD and multiple sclerosis (MS).
A high positive result strongly supports the diagnosis of MOG-antibody-associated disease, but results should always be interpreted along with your symptoms and MRI findings. Similar principles apply to aquaporin-4 (AQP4) antibodies. A negative result does not rule out NMOSD or other demyelinating diseases.
The NMO with MOG Antibody Profile is done to:
- Diagnose neuromyelitis optica spectrum disorder (NMOSD) by detecting aquaporin-4 IgG antibodies.
- Diagnose MOG antibody disease (MOGAD) through MOG IgG detection.
- Differentiate NMOSD and MOGAD from multiple sclerosis and other demyelinating diseases (conditions that damage the protective covering of nerves).
- Confirm the cause of symptoms like optic neuritis, transverse myelitis, or unexplained neurological relapses.
- Help doctors choose the right immunosuppressive medicines, because some treatments used for multiple sclerosis (MS) may not work, and may even be harmful, in NMOSD or MOGAD.
- No special preparation is required.






















